La Jolla Pharmaceutical Company CEO Buys $76,240 in Stock (LJPC)

Share on StockTwits

La Jolla Pharmaceutical Company (NASDAQ:LJPC) CEO George Tidmarsh purchased 8,000 shares of the company’s stock in a transaction that occurred on Monday, April 14th. The shares were purchased at an average cost of $9.53 per share, for a total transaction of $76,240.00. Following the completion of the purchase, the chief executive officer now directly owns 1,391,086 shares in the company, valued at approximately $13,257,050. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

LJPC has been the subject of a number of recent research reports. Analysts at Wedbush raised their price target on shares of La Jolla Pharmaceutical Company from $32.00 to $33.00 in a research note on Monday, April 7th. Separately, analysts at Noble Financial raised their price target on shares of La Jolla Pharmaceutical Company from $16.00 to $34.00 in a research note on Tuesday, March 11th. They now have a “buy” rating on the stock. Finally, analysts at Chardan Capital raised their price target on shares of La Jolla Pharmaceutical Company to $54.00 in a research note on Tuesday, March 11th. They now have a “positive” rating on the stock.

Shares of La Jolla Pharmaceutical Company (NASDAQ:LJPC) opened at 9.09 on Wednesday. La Jolla Pharmaceutical Company has a 52-week low of $0.16 and a 52-week high of $19.50. The stock has a 50-day moving average of $11.00 and a 200-day moving average of $8.86. The company’s market cap is $66.0 million.

La Jolla Pharmaceutical Company (NASDAQ:LJPC) last announced its earnings results on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.24) by $0.17. On average, analysts predict that La Jolla Pharmaceutical Company will post $-2.82 earnings per share for the current fiscal year.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the development of therapeutic agents that inhibit the activity of galectins as a means of treating human diseases such as chronic organ failure and cancer.

Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.

Latest News

De Ven Michael G. Van Sells 78,907 Shares of Southwest Airlines Stock
De Ven Michael G. Van Sells 78,907 Shares of Southwest Airlines Stock
Insider Selling: Rick Bergman Sells 11,250 Shares of Synaptics, Stock
Insider Selling: Rick Bergman Sells 11,250 Shares of Synaptics, Stock
PC Connection Director David Hall Unloads 10,000 Shares
PC Connection Director David Hall Unloads 10,000 Shares
Principal Financial Group EVP Sells $2,889,689 in Stock
Principal Financial Group EVP Sells $2,889,689 in Stock
Covanta Holding Corp Director Sells $80,820 in Stock
Covanta Holding Corp Director Sells $80,820 in Stock
Insider Selling: Lauren B. Peters Unloads 40,000 Shares of Foot Locker Stock
Insider Selling: Lauren B. Peters Unloads 40,000 Shares of Foot Locker Stock


Leave a Reply

 
© 2006-2014 Mideast Time.